Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortizatization of Intangibles: 2023-2024

Historic Amortizatization of Intangibles for Ani Pharmaceuticals (ANIP) over the last 2 years, with Dec 2024 value amounting to $13.6 million.

  • Ani Pharmaceuticals' Amortizatization of Intangibles fell 85.53% to $358,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 221.19%. This contributed to the annual value of $13.6 million for FY2024, which is 971.63% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Amortizatization of Intangibles of $13.6 million as of FY2024, which was up 971.63% from $1.3 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Amortizatization of Intangibles registered a high of $13.6 million during FY2024, and its lowest value of $1.3 million during FY2023.
  • Over the past 2 years, Ani Pharmaceuticals' median Amortizatization of Intangibles value was $7.4 million (recorded in 2023), while the average stood at $7.4 million.
  • Data for Ani Pharmaceuticals' Amortizatization of Intangibles shows a peak YoY surged of 971.63% (in 2024) over the last 5 years.
  • Over the past 2 years, Ani Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $1.3 million in 2023, then spiked by 971.63% to $13.6 million in 2024.